ARTICLE | Finance
VCs back Aspen with $147.5M as neuron replacement therapy heads toward clinic
Tapping GV, Lyfe and Revelation as series B leaders, biotech sought deep-pocketed syndicate with long-term view to match series A backer
May 9, 2022 9:04 PM UTC
With $147.5 million from a large series B syndicate, Aspen is aiming to advance its autologous, stem cell-derived Parkinson’s therapy into its first clinical study next year.
Launched in 2018, Aspen Neuroscience Inc. is developing a therapy that uses iPSCs differentiated into A9 dopaminergic neurons to replace cells that are lost or damaged during the course of Parkinson’s disease. ...